---
title: "CITIC Construction Investment: Maintains \"Buy\" rating on YUYUE MEDICAL, overseas business is expected to maintain rapid growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/242340686.md"
description: "CITIC Construction Investment Securities maintains a \"Buy\" rating on YUYUE MEDICAL, believing that its annual report performance meets expectations, with Q1 revenue slightly exceeding expectations and profits in line with expectations. It is anticipated that the recovery of domestic consumer demand and the increase in market share will drive steady growth in domestic business. At the same time, overseas business is expected to grow rapidly due to channel layout and brand building. In the short term, core businesses such as respiratory therapy and blood glucose management have strong competitiveness; in the medium to long term, the improvement of health awareness and the iteration of new products will consolidate its leading position in the domestic market and enhance its global market share"
datetime: "2025-05-29T07:37:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/242340686.md)
  - [en](https://longbridge.com/en/news/242340686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/242340686.md)
generator: "portal-rs"
---

# CITIC Construction Investment: Maintains "Buy" rating on YUYUE MEDICAL, overseas business is expected to maintain rapid growth

CITIC Construction Investment Securities' research report pointed out that YUYUE MEDICAL's annual report performance met expectations, with Q1 revenue slightly exceeding expectations and profit in line with expectations. Looking ahead to the whole year, with the recovery of domestic consumer demand and the continuous increase in the company's market share, the company's domestic business is expected to maintain a steady growth trend; as the company continues to accelerate its overseas channel layout and brand building, its overseas business is expected to maintain rapid growth. In the short term, the company's core businesses such as respiratory therapy and blood glucose management have strong market competitiveness. In the medium to long term, with the improvement of public health awareness and the continuous iteration and enrichment of the company's new products, the company's leading position in the domestic home medical device platform is expected to remain solid, and its global market share is expected to increase. Maintain a "Buy" rating

### Related Stocks

- [002223.CN](https://longbridge.com/en/quote/002223.CN.md)
- [06066.HK](https://longbridge.com/en/quote/06066.HK.md)

## Related News & Research

- [Jiangsu Yuyue Medical Equipment & Supply: Net profit fell 29.92% year-over-year, but overseas and CGM sales grew sharply](https://longbridge.com/en/news/296602713.md)
- [Xtract One CEO Evans flags “vanity metrics” in weapons detection, urges focus on capture rates](https://longbridge.com/en/news/296946614.md)
- [Quebec to hold Oct 5 election, separatists favored to win](https://longbridge.com/en/news/297209080.md)
- [Nampak director associate buys shares worth R 35.17 million](https://longbridge.com/en/news/296932706.md)
- [Lenzing shareholders approve EUR 300 million capital increase at extraordinary meeting](https://longbridge.com/en/news/296902548.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**